Loading company…
Reprieve Cardiovascular makes the Reprieve System, an automated fluid management technology for patients with acute heart failure.
Founded in 2018 and based in the US, Reprieve Cardiovascular, Inc. develops automated fluid management technology for acute heart failure patients. The Reprieve System combines real-time patient data with diuretic management and is still in investigational use. In August 2025 the company raised USD 61 million in Series B funding led by Deerfield Management, with participation from Arboretum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures and Cadence Capital Management, and plans to use it to expedite the FASTR II trial. Jim Dillon is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in